ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anemia"

  • Abstract Number: 204 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US

    Robin Dore1, Jenya Antonova 2, Magdaliz Gorritz 3, Lawrence Chang 2, Jing He 3 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3IQVIA, Plymouth meeting, PA, 4Stanford University, Stanford, CA

    Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…
  • Abstract Number: 1588 • 2019 ACR/ARP Annual Meeting

    Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?

    Chris Wincup1, Thomas McDonnell 1, George Robinson 1, Filipa Farinha 1, Anna Radziszewska 1 and Anisur Rahman 1, 1University College London, London, United Kingdom

    Background/Purpose: Haematological manifestations of SLE are common with anaemia reported in approximately 50% of cases, yet the role of altered iron metabolism is poorly understood.…
  • Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting

    Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs

    Mark Genovese1, Kenneth Kalunian 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, YingMeei Tan 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, Kurt de Vlam 6, David Walker 7 and Tsutomu Takeuchi 8, 1Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 7Northumbria Healthcare, Northumbria, United Kingdom, 8Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
  • Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting

    Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib

    Burkhard Moeller1, Axel Finckh2, Jose Maria Alvaro-Gracia3, Godehard Scholz1, Daniel Aletaha4, Francesca Biondo5, Sander Strengholt6, Jose L Rivas7, Carol A Connell8 and Harry Shi9, 1Inselspital-University Hospital, Bern, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland, 3Hospital Universitario de La Princesa, Madrid, Spain, 4Medical University of Vienna, Vienna, Austria, 5Pfizer Inc, Rome, Italy, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer SLU, Madrid, Spain, 8Pfizer Inc, Groton, CT, 9Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
  • Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting

    Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)

    Gerd R. Burmester1, Owen Hagino2, Qunming Dong3, Marina Stanislav4, Antonio Gomez-Centeno5, Carlo Selmi6, Tom W.J. Huizinga7, Erin Mangan8, Cem Gabay9 and Mark C. Genovese10, 1Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 2Sanofi Genzyme, Bridgewater, NJ, 3Sanofi, Bridgewater, NJ, 4Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, 5Corporació Sanitària Parc Taulí, Barcelona, Spain, 6Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 7Leiden University Medical Center, Leiden, Netherlands, 8Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 9University Hospitals of Geneva, Geneva, Switzerland, 10Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
  • Abstract Number: 2381 • 2017 ACR/ARHP Annual Meeting

    Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Kathleen Vanni1, Zhi Zhang1, Cassandra Corrigan2 and Daniel H. Solomon3, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Methotrexate (MTX) is known to increase the risk of cytopenias, but the prevalence of hematologic abnormalities among patients taking low dose MTX is poorly…
  • Abstract Number: 436 • 2017 ACR/ARHP Annual Meeting

    Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials

    Burkhard Moeller1, Axel Finckh2, Godehard Scholz1, Harry Shi3, Carol A Connell4 and Sander Strengholt5, 1Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Capelle aan den IJssel, Netherlands

    Background/Purpose: Anemia in patients with rheumatoid arthritis (RA) can help to identify those with more rapid erosive disease.1,2 Tofacitinib is an oral Janus kinase inhibitor…
  • Abstract Number: 1356 • 2016 ACR/ARHP Annual Meeting

    Correlation of Erythrocyte Sedimentation Rate with Glycohemoglobin Values and Other Patient Factors

    Brian LaMoreaux, Dept of Internal Medicine, Division of Rheumatology, The Ohio State University, Columbus, OH

    Background/Purpose: The erythrocyte sedimentation rate (ESR) is a laboratory test commonly used in clinical practice as an assessment of systemic inflammation. The glycohemoglobin (A1c) measures…
  • Abstract Number: 1803 • 2016 ACR/ARHP Annual Meeting

    General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia

    Regaip Elezi1, Gulsum Emel Pamuk2, Muhammet Maden2, Mehmet Ali Balci1,3 and Omer Nuri Pamuk1, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Hematology, Trakya University Medical Faculty, Edirne, Turkey, 3Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey

    Background/Purpose:  Anemia in systemic lupus erythematosus (SLE) might have various etiologies; however, autoimmune hemolytic anemia (AIHA) is the characteristic hematologic feature. AIHA might be primary…
  • Abstract Number: 728 • 2015 ACR/ARHP Annual Meeting

    Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival

    Bahar Artim-Esen1, Sevil Kamali1, Ahmet Gul1, Lale Ocal2 and Murat Inanc1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: Hematologic involvement is common in patients with SLE. Thrombocytopenia and autoimmune hemolytic anemia (AIHA), prevalences of which have been reported as 10-40 % and…
  • Abstract Number: 831 • 2015 ACR/ARHP Annual Meeting

    Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis

    Tiffany Lin1, James Bena2, Shannon Morrison2 and Soumya Chatterjee3, 1Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Gastric antral vascular ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal bleeding in patients with systemic sclerosis (SSc).  These patients may require…
  • Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency

    Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan

    Background/Purpose:  Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
  • Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting

    Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus

    Eugenia Enriquez Merayo1, Maria Galindo Izquierdo2, Esther Rodriguez-Almaraz3, Maria Martin Lopez2, Otto Martin Olivas Vergara4, Patricia E. Carreira5 and Isabel Mateo6, 1RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, 2RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 3Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 4HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 5Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, 6Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain

    Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
  • Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting

    Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects

    Jeffrey Voss1, Candace Graff2, Annette Schwartz3, Deborah Hyland4, Maria Argiriadi4, Heidi Camp5, Lori Dowding4, Michael Friedman4, Kristine Frank5, Jonathon George4, Eric Goedken4, Gloria Lo Schiavo4, Michael Morytko4, Robert o'Brien4, Robert Padley6, Matthew Rosebraugh5, Michael Rozema5, Kent Stewart5, Grier Wallace4, Neil Wishart4, Anwar Murtaza7 and Lisa Olson3, 1Immunology, AbbVie Pharmaceuticals, Worcester, MA, 2Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Abbvie Pharmaceuticals, worcester, MA, 5abbvie pharmaceuticals, north chicago, IL, 6AbbVie, Inc, North Chicago, IL, 7Broad Institute, Cambridge, MA

    Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
  • Abstract Number: 735 • 2013 ACR/ARHP Annual Meeting

    Clinical Research Of Microscopic Polyangiitis Combined With Autoimmune Hemolytic Anemia

    Dan Liu1,2,3, Qing-ping Chen4, Hai-hong Yao5, Ru Li1, Yin Su1, Jie Zhang4, Yu Chen4, Ke Li3 and Yuan Jia1, 1Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi'an, China, 3Core Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China, 4Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi’an, China, 5Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose: Autoimmune hemolytic anemia (AIHA) and Microscopic polyangiitis (MPA) are both rare autoimmune conditions. AIHA is caused by autoantibody-induced hemolysis (the premature destruction of circulating…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology